Statera Biopharma is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. Statera has one of the largest platforms of toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. TLRs are a class of protein that plays a key role in the innate immune system. Statera is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. Statera has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis.
Company profile
Ticker
STAB
Exchange
Website
CEO
Christopher Zosh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CLEVELAND BIOLABS INC, Cytocom, Inc.
SEC CIK
Corporate docs
Subsidiaries
High Street Acquisition Corporation • Panacela Labs, Inc. • Panacela Labs LLC ...
IRS number
200077155
STAB stock data
News
12 Health Care Stocks Moving In Friday's After-Market Session
5 Aug 22
Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket
1 Aug 22
Stocks That Hit 52-Week Lows On Thursday
28 Jul 22
IBM And 20 Stocks Moving Premarket
19 Jul 22
12 Health Care Stocks Moving In Friday's Pre-Market Session
15 Jul 22
Investment data
Securities sold
Number of investors
Calendar
31 Mar 22
15 Aug 22
31 Dec 22
Financial summary
| Quarter (USD) | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 14.22M | 14.22M | 14.22M | 14.22M | 14.22M | 14.22M |
| Cash burn (monthly) | (no burn) | (no burn) | 3.21M | 554.71K | 6.28M | 1.17M |
| Cash used (since last report) | n/a | n/a | 33.87M | 5.84M | 66.17M | 12.36M |
| Cash remaining | n/a | n/a | -19.65M | 8.37M | -51.96M | 1.86M |
| Runway (months of cash) | n/a | n/a | -6.1 | 15.1 | -8.3 | 1.6 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 Sep 21 | Taunia Markvicka | Common Stock, par value $0.005 per share | Grant | Acquire A | No | No | 0 | 100,000 | 0 | 100,000 |
| 9 Sep 21 | Barbarick Steve K | Common Stock, par value $0.005 per share | Grant | Acquire A | No | No | 0 | 60,000 | 0 | 60,000 |
| 9 Sep 21 | Lea Verny | Common Stock, par value $0.005 per share | Grant | Acquire A | No | No | 0 | 60,000 | 0 | 60,000 |
| 9 Sep 21 | Randy S. Saluck | Common Stock, par value $0.005 per share | Grant | Acquire A | No | No | 0 | 60,000 | 0 | 60,140 |
Institutional ownership, Q1 2022
5.4% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 29 |
| Opened positions | 9 |
| Closed positions | 9 |
| Increased positions | 7 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 761K |
| Total shares | 2.12M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 389.11K | $122K |
| Empery Asset Management | 333.02K | $105K |
| Renaissance Technologies | 171.92K | $54K |
| NTRS Northern Trust | 171.11K | $54K |
| VIRT Virtu Financial | 157.68K | $50K |
| Geode Capital Management | 130.77K | $41K |
| UBS UBS Group AG - Registered Shares | 118.67K | $37K |
| Raymond James Financial Services Advisors | 112.25K | $35K |
| Two Sigma Securities | 78.19K | $25K |
| Cambridge Investment Research Advisors | 70.25K | $22K |
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
academic, accrual, adaptive, added, advertising, advice, agency, agonist, Allocate, allocated, allocation, America, anemia, anniversary, arose, ASC, assessment, assist, augment, bacteria, behalf, biopharma, Black, Bridgeway, bundled, California, central, charged, chronic, client, Committee, compound, comprise, concentration, courier, coverage, CRO, Crohn, culmination, Decathlon, decision, deficit, demand, depreciation, deterioration, disagreement, disbursement, disclaimer, discovery, discretionary, distinct, distribution, doubt, doubtful, earlier, efficacy, employment, enable, entity, ERP, eventual, exceed, expenditure, explanatory, explicit, explicitly, explore, expressed, factor, FDIC, fell, final, finalization, finalized, finite, firm, fixed, foreseeable, forma, frequently, Ft, furniture, goodwill, grew, Griffin, guidance, haul, headcount, heavily, hematology, higher, hire, hired, immunology, implicit, implied, important, inability, incremental, innate, insignificant, insurance, insured, internet, Jolla, La, laboratory, leader, leadership, leave, left, light, lived, LJI, LLP, Maryland, maximum, Meaden, mechanism, modulation, Moore, Multiplied, mutual, neutropenia, NIH, Noreen, oral, Organization, pancreatic, paper, parent, passage, patent, payoff, payroll, pediatric, physical, pipeline, pivotal, play, possession, postage, predecessor, preliminary, prepaid, principle, pro, procedure, promised, proportionally, protein, purported, purpose, qualified, Qualitative, quantitatively, question, reached, reaching, recapitalization, receipt, recipient, recovery, relevant, remitted, remote, remove, removed, rendered, repurchase, resource, retroactively, reversal, reverse, role, rose, routine, scope, screening, select, selected, shut, space, STAB, statera, Step, Stone, structure, subscription, successful, symbol, telecommunication, title, toxicity, treatment, trust, Turner, type, typically, uncollectable, unpaid, write, written
Removed:
aimed, annually, Article, assignment, assumption, Authority, awarded, BARDA, biodefense, Biomedical, CDMRP, Congressionally, consolidation, critical, CSO, derived, detailed, disrupted, DoD, eliminated, footnote, founding, innovative, intercompany, JWMRP, matching, Norma, Peer, PRMRP, proportional, reduction, Reviewed, shutdown, significantly, subsequently, testing, treasury, variant, variety, Warfighter
Current reports
8-K
Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting firm
3 Aug 22
8-K
Departure of Directors or Certain Officers
22 Jun 22
8-K
Departure of Directors or Certain Officers
6 Jun 22
8-K
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing
27 May 22
8-K
Departure of Directors or Certain Officers
27 Apr 22
8-K
Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod
18 Apr 22
8-K
Changes in Registrant's Certifying Accountant
15 Apr 22
8-K/A
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Apr 22
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
31 Mar 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
25 Mar 22
Registration and prospectus
424B5
Prospectus supplement for primary offering
23 Mar 22
424B5
Prospectus supplement for primary offering
22 Mar 22
424B5
Prospectus supplement for primary offering
7 Feb 22
424B5
Prospectus supplement for primary offering
10 Sep 21
425
Business combination disclosure
17 Jun 21
424B3
Prospectus supplement
10 Jun 21
S-4/A
Registration of securities issued in business combination transactions (amended)
7 May 21
424B5
Prospectus supplement for primary offering
22 Feb 21
425
Business combination disclosure
17 Feb 21
Other
EFFECT
Notice of effectiveness
11 Jun 21
CORRESP
Correspondence with SEC
7 Jun 21
CORRESP
Correspondence with SEC
3 Jun 21
UPLOAD
Letter from SEC
23 May 21
CORRESP
Correspondence with SEC
6 May 21
UPLOAD
Letter from SEC
24 Feb 21
EFFECT
Notice of effectiveness
1 Jun 20
UPLOAD
Letter from SEC
27 May 20
CORRESP
Correspondence with SEC
26 May 20
CT ORDER
Confidential treatment order
16 Nov 17
Ownership
3
Statera Biopharma / Satishchandran Chandrasekhar ownership change
21 Mar 22
SC 13G/A
Statera Biopharma / HARPEL JAMES W ownership change
14 Feb 22
4
Statera Biopharma / RANDY S. SALUCK ownership change
28 Oct 21
4
Statera Biopharma / Steve K Barbarick ownership change
19 Oct 21
4
Statera Biopharma / Lea Verny ownership change
19 Oct 21
4
Statera Biopharma / Taunia Markvicka ownership change
30 Sep 21
4
Cytocom / Michael K Handley ownership change
4 Aug 21
3
Cytocom / Michael K Handley ownership change
4 Aug 21
4
Cytocom / Robert Buckheit ownership change
29 Jul 21
4
Cytocom / Clifford Selsky ownership change
29 Jul 21
Patents
Utility
Use of Toll-like Receptor Agonist for Treating Cancer
10 Jun 21
The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin.
Utility
Methods and compositions for the treatment of radiation-related disorders
7 Dec 20
This invention relates, in part, to methods and compositions that are useful for the treatment and/or prevention of various disorders, including radiation-related disorders, such as acute radiation syndrome.
Utility
Use of toll-like receptor agonist for treating cancer
21 Sep 20
The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin.
Reddit threads
Daily Discussion Thread - August 15th, 2022
15 Aug 22
Daily Discussion Thread - August 12th, 2022
12 Aug 22
Euro falls below dollar parity. How could I capitalize on this?
14 Jul 22
Picks for July 1st, 2022
1 Jul 22
Daily Plays May 13, 2022
13 May 22
Daily Plays May 10, 2022
10 May 22
Daily Plays May 06, 2022
6 May 22
Daily Plays May 05, 2022
5 May 22
Daily Plays May 04, 2022
4 May 22
Daily Plays May 03, 2022
3 May 22